F-group (family)
1.1.1.1 Asp
Ligands and drugs
4,270
Member domains
2,619
with ligand contacts (≤ 4 Å)
61.3% of members
2,383
with DrugDomain annotations
55.8% of members
1,106
with a DrugBank compound
25.9% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 1.1.1.1 belongs to X-group 1 cradle loop barrel, which binds 9.4 ligand superclasses per 20 proteins, broader than 87% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02078 | PG5 | Triglyme | 88 |
| DB09459 | TLA | L-tartaric acid | 51 |
| DB00141 | NAG | N-Acetylglucosamine | 41 |
| DB01694 | TAR | D-tartaric acid | 26 |
| DB03904 | URE | Urea | 12 |
| DB00503 | RIT | Ritonavir | 10 |
| DB02676 | B3P | 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol | 10 |
| DB12285 | 66F | Verubecestat | 8 |
| DB03843 | FOR | Formaldehyde | 7 |
| DB07874 | H24 | (6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one | 6 |
| DB08749 | XX4 | 3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE | 6 |
| DB02668 | JE2 | JE-2147 | 4 |
| DB12547 | 3YS | LY-2886721 | 4 |
| DB13065 | 4B2 | LY-2811376 | 4 |
| DB07415 | B35 | 4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine | 3 |
| DB07737 | F1K | (2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide | 3 |
| DB00201 | CFF | Caffeine | 2 |
| DB00212 | REM | Remikiren | 2 |
| DB00368 | LNR | Norepinephrine | 2 |
| DB01232 | ROC | Saquinavir | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| IOD | IODIDE ION | 130 |
| U1H | [4-(trifluoromethyl)phenyl]methanamine | 92 |
| PG5 | 1-METHOXY-2-[2-(2-METHOXY-ETHOXY]-ETHANE | 90 |
| ZNmetal | ZINC ION | 65 |
| NAmetal | SODIUM ION | 64 |
| TLA | L(+)-TARTARIC ACID | 58 |
| CL | CHLORIDE ION | 32 |
| TAR | D(-)-TARTARIC ACID | 31 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 30 |
| MAN | alpha-D-mannopyranose | 19 |
| 006 | (4R)-3-[(2S,3S)-3-{[(2,6-dimethylphenoxy)acetyl]amino}-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide | 16 |
| NImetal | NICKEL (II) ION | 14 |
| URE | UREA | 14 |
| 0BI | (4S)-4-[(1R)-1-hydroxy-2-({1-[3-(1-methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-hexaen-2-one | 12 |
| 957 | N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({1-[4-(2,2-dimethylpropyl)thiophen-2-yl]cyclopropyl}amino)-2-hydroxypropyl]acetamide | 12 |
| AFJ | (2R,4S,5S)-N-butyl-4-hydroxy-2,7-dimethyl-5-{[N-(4-methylpentanoyl)-L-methionyl]amino}octanamide | 12 |
| AR9 | (2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl]-4-hydroxy-2-methylbutanamide | 12 |
| AXF | (2R,4S)-N-BUTYL-4-HYDROXY-2-METHYL- 4-((E)-(4AS,12R,15S,17AS)-15-METHYL -14,17-DIOXO-2,3,4,4A,6,9,11,12,13, 14,15,16,17,17A-TETRADECAHYDRO-1H-5 ,10-DITHIA-1,13,16-TRIAZA-BENZOCYCL OPENTADECEN-12-YL)-BUTYRAMIDE | 12 |
| AXQ | {(E)-(3R,6S,9R)-3-[(1S,3R)-3-((S)-1 -BUTYLCARBAMOYL-2-METHYL-PROPYLCARB AMOYL)-1-HYDROXY-BUTYL]-6-METHYL-5, 8-DIOXO-1,11-DITHIA-4,7-DIAZA-CYCLO PENTADEC-13-EN-9-YL}-CARBAMIC ACID TERT-BUTYL ESTER | 12 |
| BAV | (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione | 12 |